![doctors meeting](http://blog-ecog-acrin.org/wp-content/plugins/revslider/public/assets/assets/dummy.png)
July 3, 2024
GI Cancer Committee displays strong representation at ASCO; real-world data study nears activation; ECOG-ACRIN commends NCI's appointment of senior advisor for clinical research
July 3, 2024
This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial
July 3, 2024
The changes broaden eligibility for patients and permit more therapeutic options once enrolled in this randomized phase 3 trial, which explores the addition of radiotherapy to the usual treatment (chemotherapy) in people with esophagus and stomach cancer with limited spread
July 3, 2024
Summaries of recently published ECOG-ACRIN research results
July 3, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more